Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 756 participants.

Also called NCT01652872

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 756 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01652872
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01652872. Randomized; triple masking; primary purpose treatment. Start 2012-07-30 (actual); primary completion 2017-10-19 (actual). Results posted on 2018-11-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Acronym
START-CKD
Condition
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Intervention (Biological)
Darbepoetin alfa
Intervention (Other)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01652872
Content hash
8453183b1b89a5e35dca86a1217d56888b47a06498b9217987d384e6f3feb74e